8-K: Glucotrack Faces Nasdaq Delisting Risks

Glucotrack, Inc. has received notice of potential delisting from Nasdaq due to failure to meet minimum bid price and stockholders' equity requirements.

Summary

• Glucotrack received a Staff Determination letter on May 11, 2026, regarding non-compliance with the Nasdaq minimum bid price rule of $1.00 per share.
• On May 15, 2026, the company received a second notice regarding failure to meet the $2,500,000 minimum stockholders' equity requirement.
• The company intends to request a hearing before a Nasdaq Hearings Panel by May 18, 2026, to appeal the delisting determinations.
• A timely hearing request will stay delisting actions while the appeal process is pending.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a high-risk development, as the company is facing dual threats to its Nasdaq listing status, which significantly increases uncertainty for shareholders.

Positives

• The company is actively engaging with the Nasdaq process to appeal the delisting determination.
• The filing of a timely hearing request provides a temporary stay of delisting actions.

Negatives

• The company is currently in violation of two separate Nasdaq continued listing standards.
• The company failed to meet the $2,500,000 minimum stockholders' equity requirement as of March 31, 2026.
• The company's common stock is trading below the $1.00 minimum bid price requirement.
• There is no guarantee that the appeal to the Nasdaq Hearings Panel will be successful.

Risks

• Potential delisting from The Nasdaq Capital Market.
• Inability to regain compliance with Nasdaq listing rules.
• Potential negative impact on stock liquidity and investor confidence due to delisting proceedings.
• Uncertainty regarding the outcome of the upcoming Nasdaq hearing.

Future Outlook

The company intends to present a plan to regain compliance with Nasdaq listing rules at a scheduled hearing, though success is not guaranteed.

Management Comments

• The company intends to timely request a hearing before a Nasdaq Hearings Panel to appeal the determination.
• The company expects to present its plan to regain compliance with the Bid Price Rule at the hearing.

Industry Context

StockSavvy.ai notes that small-cap medical technology firms frequently face Nasdaq compliance hurdles during periods of capital intensity or R&D-heavy phases, often requiring reverse splits or capital raises to rectify equity and price deficiencies.

Comparison to Industry Standards

• The company's struggle to maintain a $2.5M equity floor is common among early-stage biotech/medtech firms.
• Nasdaq's strict enforcement of the $1.00 bid price rule is a standard regulatory hurdle for micro-cap equities.

Stakeholder Impact

• Shareholders face potential loss of liquidity if the stock is delisted to the OTC markets.
• Creditors may reassess risk profiles given the company's equity deficiency.

Next Steps

• Submit a formal request for a hearing to the Nasdaq Hearings Panel by May 18, 2026.
• Prepare and present a compliance plan to the Nasdaq Hearings Panel.

Key Dates

Recommendation

The combination of a bid price deficiency and a failure to meet minimum equity requirements signals significant financial distress and high execution risk, warranting a cautious or sell stance until a clear path to compliance is established.

Keywords

Glucotrack, GCTK, Nasdaq, Delisting, Compliance, Stockholders Equity, Bid Price Rule